Highlights
- Integral Diagnostics (ASX:IDX) disclosed operating NPAT of AUD 47.4mn (up 50.1% YoY) for FY26.
- The company reported operating EBITDA margin of 20.9%, with in line with guidance.
- The company disclosed cash conversion of 82.0%, leverage of 2.3 times and a final fully franked dividend of 6.0 cents per share.
Integral Diagnostics (ASX:IDX) operates in diagnostic imaging services and provides radiology and clinical imaging centres. Its latest material company statement, released on 25 August 2026, describes performance for FY26. The latest operational and financial disclosure is discussed separately from daily share-price trading.
What Did the 25 August 2026 Announcement Report?
In the statement dated 25 August 2026, Integral Diagnostics (ASX:IDX) disclosed operating NPAT of AUD 47.4mn. The comparison was up 50.1% YoY. This is a company-reported performance indicator for FY26, and should be read in the context of the company’s business model and the accounting or operating definitions used in the release. The update also identifies operating EBITDA margin of 20.9%, with the associated comparison described as in line with guidance. Those two measures capture different aspects of performance and are not interchangeable.
Financial Results and Operating Measures
The FY26 release presents operating NPAT alongside operating EBITDA margin. For Integral Diagnostics (ASX:IDX), reporting both is relevant because the business combines radiology and clinical imaging centres. Revenue and operating indicators describe the level of activity, while earnings or contract-based measures can reflect different timing, costs and recognition methods. The statement records the figures as AUD 47.4mn and 20.9%, respectively. Any comparison with previous reporting periods needs to use the same metric definition and reporting currency.
Operational Developments and Business Execution
The company disclosed cash conversion of 82.0%, leverage of 2.3 times and a final fully franked dividend of 6.0 cents per share. The disclosure sets out the company’s operational priorities and related performance indicators. Contract wins, recurring service delivery, product deployment and customer activity, where relevant, are separate indicators from recognised revenue. The financial outcome depends on the nature and timing of the services or products delivered.
Company Profile and Business Overview
Integral Diagnostics (ASX:IDX) is an Australian-listed business focused on diagnostic imaging services. Its activities include radiology and clinical imaging centres. The operating model shapes which activity indicators accompany reported earnings, including, where applicable, contract volumes, platform usage, licensing, adoption or project delivery. The FY26 release is therefore most usefully read using the specific figures attributed to Integral Diagnostics (ASX:IDX), without importing metrics from unrelated companies.
Risks and Catalysts on Watch
Workforce availability, acquisition integration, reimbursement and funding costs affect diagnostic-imaging operators. The next reported period may also provide additional information on order conversion, customer demand, cash generation, financing, product implementation and the extent to which previously disclosed plans have proceeded. These factors will be reflected in subsequent company updates when further financial or operational information is reported.
Key Insights
The main factual developments for Integral Diagnostics (ASX:IDX) are its FY26 disclosure of operating NPAT at AUD 47.4mn, the reported operating EBITDA margin of 20.9%, and the operational information described above. The publication date was 25 August 2026. These measures should be retained with their precise period and accounting descriptions, especially when comparing the company with other ASX-listed small-cap businesses. Further updates may clarify how operating activity affects subsequently reported earnings and cash flow.






Please wait processing your request...